CLEC4A

Across TCGA pan-cancer cohorts, CLEC4A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CLEC4A data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CLEC4A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLEC4A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, BRCA, and LIHC are the cancer types where CLEC4A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.201	0.720	.005	18	view →
BRCA	OS	Median	All	0.115	0.578	.011	18	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.629	.025	6	view →
COAD	OS	Median	II,III,IV	0.184	0.785	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CLEC4A–BLCA (OS)

Open the BLCA breakdown →